Epizyme, Inc. (EPZM): Robert A Copeland , President of Research and CSO of Epizyme, Inc. sold 4,000 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 7, 2016 to the Securities and Exchange Commission. The shares were sold at $10.03 per share for a total value of $40,127.60 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, Andrew E. Singer (EVP & CFO) sold 1,013 shares at $12.49 per share price.On Mar 2, 2016, Peter Tai-ching Ho (Chief Development Officer) purchased 636 shares at $7.47 per share price.Also, On Jan 12, 2016, Peter J Barris (10% owner) purchased 1,111,111 shares at $9.00 per share price.On Jan 12, 2016, Krishna Kittu Kolluri (10% owner) purchased 1,111,111 shares at $9.00 per share price.
Shares of Epizyme Inc (EPZM) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.32 points or -3.10% at $10.01 with 1,97,455 shares getting traded. Post opening the session at $10.21, the shares hit an intraday low of $9.85 and an intraday high of $10.29 and the price vacillated in this range throughout the day. The company has a market cap of $573 M and the number of outstanding shares has been calculated to be 5,72,22,744 shares. The 52-week high of Epizyme Inc is $25.25 and the 52-week low is $8.27.
Company has been under the radar of several Street Analysts.Epizyme Inc is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 18 from a previous price target of $20 . The Rating was issued on May 10, 2016.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.